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The human being is genomically similar to a chimpanzee, while phenotypicallydifferent.1,2 Most of the differences are due to a relatively small number of changes in
gene regulation, implying that small genomic differences may cause significant pheno-
typic diversities. Simple base-pair deletion at epidermal growth factor receptor (EGFR)
exon 19 or single point mutation at EGFR exon 21 has dramatically shifted the treatment
paradigm of patients with advanced non-small cell lung cancer. Most patients with the
mutation will likely respond to EGFR tyrosine kinase inhibitor (TKI) such as gefitinib or
erlotinib and benefit from a prolonged duration of progression-free survival.3–5 EGFR TKI
is now considered a standard first-line therapy for patients harboring the EGFR mutation.
The key issue is to identify these patients in daily practice, thus population-based
incidence rate will be an important guide to oncologists.
Helland et al.6 reported in the current issue of Journal of Thoracic Oncology the
EGFR mutation rate of 7.5% in Norwegian patients with resectable early-stage non-small
cell lung cancer. This represents the first report from northern Europe. Authors chose to
study the incidence on resected lung tumor to reduce sample bias. Their decision assures
sufficient tumor sample for EGFR mutation analysis, but their result may not be directly
comparable with other existing reports on EGFR mutations that were conducted in
patients with advanced-stage disease. The truth is that the current clinical indication for
EGFR TKI is for patients with stage IV lung cancer with EGFR mutation. We cannot
assume the incidence of EGFR mutation in early-stage lung cancer to be representative of
patients with advanced-stage disease.
Diversity in incidence of EGFR mutation may partly be explained by the diversity
in population selection. The highest incidence of EGFR mutation reported in a white
population was 35%, in which the study population included only adenocarcinoma and
38% of whom were never smokers.7 In unselected white population, the incidence ranges
from 4.5 to 16.6%.8,9 Smoking history of the study population contributes to the incidence.
The number of pack years of smoking is in reverse proportion to the frequency of
mutations.10 Patients with more than 15 pack-year tobacco consumption has a far lower
chance of harboring EGFR mutation. Unfortunately, most of the population-based study
only classified patient qualitatively as never, former, or current smoker and failed to
include quantitative documentation on tobacco consumption. In the report by Helland et
al., previous smoker was defined as having stopped smoking at least 1 year before surgery.
This definition would have limited correlation with the chance of harboring EGFR
mutation. A patient with 30 pack-year history of tobacco consumption and who quit over
1 year before would have much lower incidence than a patient with 10 pack-year history
and quitted for the same duration. Authors included only 15 never smokers in the study
population of 240 Norwegians and failed to report the national statistics on never smoker
with lung cancer in their country. Expectedly, 8 (53%) of the 15 never smokers were
positive for EGFR mutation. If more “never smokers” were included in the study
population, the overall incidence would be higher than 7.5%. Therefore, the “apparent”
ethnic-based incidence depends on proportion of never smokers in the study population.
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Diversity in testing methods may also explain the
difference in incidence of EGFR mutation. Direct sequencing
is considered the standard testing method. Nevertheless, sen-
sitivity of the test is limited by the relative abundance of
mutated allele versus the wild-type allele. False-negative rate
is estimated at 10% pending on the quality of the tumor
sample.11 Other testing methods such as Scorpion ARMS
(Therascreen EGFR mutation kit by DxS, Manchester, UK)
or denaturing high-performance liquid chromatography are
more sensitive, but the Scorpion Amplification Refractory
Mutation System limits to 28 known mutations at the EGFR
gene and may miss other mutations. Iressa Pan-Asia Study
and First-line Single Agent Iressa versus Gemcitabine and
Cisplatin Trial in Never-smokers with Adenocarcinoma of
the Lung share similarity in study population including only
Asian nonsmokers with adenocarcinoma, but the incidence of
EGFR mutation was 59.7% (261/437) and 43.8% (42/96),
respectively.3,12 The 16% difference could be explained by
the different testing method. Iressa Pan-Asia Study used
Scorpion ARMS, and tumor response rate to gefitinib in
patients without EGFR mutation was 1.1%, suggesting a very
low false-negative rate. First-line Single Agent Iressa versus
Gemcitabine and Cisplatin Trial in Never-smokers with Ad-
enocarcinoma of the Lung used direct sequencing, and 7
(25.9%) of 27 mutation “negative” patients responded to
gefitinib. The high tumor response rate in their mutation-
negative patient is best explained by false-negative rate of the
testing method, and the false-negative rate explained the
difference in incidence of the two study populations.
Rate is a ratio of two measurements. Difference in rate
between two populations will have little meaning if measure-
ments of the denominators are not the same. In comparison of
EGFR mutation rate between ethnicity, it is essential to
assure the study populations sharing the same proportion of
adenocarcinoma, tobacco consumption, and testing methods.
The observation of a higher EGFR mutation rate in East
Asian is likely a true phenomenon, but the smaller variations
between other ethnicities could be explained by diversities in
the study populations.
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